Breaking News Instant updates and real-time market news.

REPH

Recro Pharma

$7.76

-0.23 (-2.88%)

07:13
11/28/16
11/28
07:13
11/28/16
07:13

Recro Pharma meloxicam Phase III clinical trial achieves primary endpoint

Recro Pharma announced positive results from its second of two Phase III clinical trials evaluating intravenous meloxicam for the treatment of acute postoperative pain. In this trial, IV meloxicam achieved the primary endpoint of a statistically significant difference in Summed Pain Intensity Difference, or SPID, over the first 24 hours, or SPID24, compared to placebo, in patients following abdominoplasty surgery. With the positive data from this study, the company believes this completes the efficacy program for the IV meloxicam New Drug Application, or NDA. In this multicenter, randomized, double-blind, placebo-controlled clinical trial, 219 patients were enrolled and randomly assigned to receive a postoperative regimen of IV meloxicam or placebo in a 1:1 ratio, once every 24 hours. The IV meloxicam treatment arm demonstrated a statistically significant reduction in SPID24 compared to the placebo arm. The study also achieved statistical significance for 10 of the secondary endpoints, including statistically significant differences in SPID12, time to perceptible pain relief, subjects with greater than or equal to 30% improvement at 24 hours, number of times patients required rescue in the first 24 hours after randomization, as well as number of times rescued from 24 to 48 hours, and several other pain relief metrics, compared to placebo. The safety results demonstrated that IV meloxicam was well tolerated with no difference in serious adverse events, or SAEs, related to bleeding for IV meloxicam treated patients versus placebo. There were two additional SAEs observed in the placebo group. The most common adverse events, or AEs, were nausea, headache, vomiting, and dizziness. The incidence of these events was lower than those observed in the placebo group. The majority of AEs were mild in nature and one patient in the placebo group discontinued treatment due to an adverse event of post-procedural bleeding. There were no meaningful differences between treatment groups in vital signs, ECGs or clinical lab assessments.

  • 29

    Nov

REPH Recro Pharma
$7.76

-0.23 (-2.88%)

08/29/16
JANY
08/29/16
INITIATION
JANY
Buy
Recro Pharma initiated with a Buy at Janney Capital
Target $21.
08/29/16
08/29/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Sell at Axiom by analyst Victor Anthony, who set an $80 price target on shares of the streaming service operator. The company's is seeing rising competition and diminishing pricing power, Anthony tells investors in a research note. He adds that rising content costs will pressure Netflix's ability to meet Street estimates. 2. Invuity (IVTY) initiated with a Buy rating and $25 price target by Craig-Hallum analyst Charles Haff, who believes the company's surgical lighting products offer higher quality resolution and are safer and more effective than the current standard of care in minimally-invasive procedures. 3. Recro Pharma (REPH) initiated by Janney Capital analyst Ken Trbovich with a Buy rating and $21 fair value estimate. 4. Neuralstem (CUR) initiated by Roth Capital analyst Joseph Pantginis with a Buy rating and $1.20 price target. 5. At Home Group (HOME) initiated with an Outperform rating at William Blair and with a Buy rating and $20 price target at Jefferies. To see The Fly's full Street Research coverage, Reference Link
09/16/16
ROTH
09/16/16
INITIATION
Target $24
ROTH
Buy
Recro Pharma initiated with a Buy at Roth Capital
Roth Capital analyst Scott Henry started Recro Pharma with a Buy rating and $24 price target.
10/03/16
BMUR
10/03/16
INITIATION
Target $21
BMUR
Buy
Recro Pharma coverage assumed with a Buy at Brean Capital
Brean Capital analyst Difei Yang assumed coverage on Recro Pharma with a Buy rating citing upcoming catalysts and its lead product candidate which could serve as a non-opioid alternative for pain management. Yang placed a $21 price target on Recro Pharma shares, which is reduced from the firm's prior price target of $28.

TODAY'S FREE FLY STORIES

ANF

Abercrombie & Fitch

$12.19

0.14 (1.16%)

10:10
06/22/17
06/22
10:10
06/22/17
10:10
Upgrade
Abercrombie & Fitch rating change  »

Abercrombie & Fitch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$11.43

0.59 (5.44%)

10:10
06/22/17
06/22
10:10
06/22/17
10:10
Options
5K Horizon Pharm Jan 15 calls opened for 89c when bid-ask was 45 to 90c »

5K Horizon Pharm Jan 15…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATUS

Altice USA

10:08
06/22/17
06/22
10:08
06/22/17
10:08
Syndicate
Altice USA indicated to open at $31.50, IPO priced at $30 »

Altice USA (ATUS) priced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

CVM

CEL-SCI

$1.80

0.11 (6.51%)

10:08
06/22/17
06/22
10:08
06/22/17
10:08
Hot Stocks
Breaking Hot Stocks news story on CEL-SCI »

Cel Sci trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$17.93

0.15 (0.84%)

10:07
06/22/17
06/22
10:07
06/22/17
10:07
Technical Analysis
Technical View: Twitter bounces higher for second session »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 19

    Jul

SGBX

SG Blocks

10:06
06/22/17
06/22
10:06
06/22/17
10:06
Syndicate
Breaking Syndicate news story on SG Blocks »

SG Blocks opens at $4.75,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

IGLD

Internet Gold

10:06
06/22/17
06/22
10:06
06/22/17
10:06
Hot Stocks
Breaking Hot Stocks news story on Internet Gold »

Internet Gold trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACN

Accenture

$121.52

-5.59 (-4.40%)

10:04
06/22/17
06/22
10:04
06/22/17
10:04
Technical Analysis
Technical View: Accenture trades near lows of the day »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

GM

General Motors

$34.06

-0.07 (-0.21%)

10:04
06/22/17
06/22
10:04
06/22/17
10:04
Hot Stocks
GM reports 'successful' conclusion of three-year consent order with NHTSA »

General Motors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

10:01
06/22/17
06/22
10:01
06/22/17
10:01
General news
Leading Indicators data reported »

May Leading Indicators up…

IGLD

Internet Gold

10:01
06/22/17
06/22
10:01
06/22/17
10:01
Hot Stocks
Breaking Hot Stocks news story on Internet Gold »

Internet Gold trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$17.85

0.0699 (0.39%)

10:01
06/22/17
06/22
10:01
06/22/17
10:01
Hot Stocks
Twitter, Sela Sport announce live streaming partnership »

Twitter and Sela Sport…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 19

    Jul

QQQ

PowerShares QQQ Trust

$140.74

1.38 (0.99%)

10:00
06/22/17
06/22
10:00
06/22/17
10:00
Options
Bullish three-way spread in PowerShares QQQ »

Bullish three-way spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRTO

Proteon Therapeutics

10:00
06/22/17
06/22
10:00
06/22/17
10:00
Hot Stocks
Breaking Hot Stocks news story on Proteon Therapeutics »

Proteon Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XXII

22nd Century

$1.81

-0.005 (-0.28%)

09:58
06/22/17
06/22
09:58
06/22/17
09:58
Hot Stocks
22nd Century receives guidance from FDA on Phase 3 clinical trials »

22nd Century announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFIE

Profire Energy

$1.31

-0.01 (-0.76%)

09:57
06/22/17
06/22
09:57
06/22/17
09:57
Conference/Events
Profire Energy management to meet with Maxim »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

WB

Weibo

$76.96

2.88 (3.89%)

, MOMO

Momo

$38.70

0.81 (2.14%)

09:55
06/22/17
06/22
09:55
06/22/17
09:55
Recommendations
Weibo, Momo analyst commentary  »

Jefferies sees no…

WB

Weibo

$76.96

2.88 (3.89%)

MOMO

Momo

$38.70

0.81 (2.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$50.76

4.43 (9.56%)

, SPLS

Staples

$8.66

-0.09 (-1.03%)

09:55
06/22/17
06/22
09:55
06/22/17
09:55
Options
Early notable gainers among liquid option names on June 22nd »

Notable gainers among…

ORCL

Oracle

$50.76

4.43 (9.56%)

SPLS

Staples

$8.66

-0.09 (-1.03%)

KMX

CarMax

$62.14

2.4001 (4.02%)

RL

Ralph Lauren

$72.50

1.59 (2.24%)

UA

Under Armour

$18.93

0.18 (0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 29

    Jun

  • 30

    Jun

CBRL

Cracker Barrel

$162.44

-0.9 (-0.55%)

09:51
06/22/17
06/22
09:51
06/22/17
09:51
Conference/Events
Cracker Barrel management to meet with Maxim »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

ATUS

Altice USA

09:51
06/22/17
06/22
09:51
06/22/17
09:51
Syndicate
Altice USA IPO indicated to open at $31 on 2.3M »

Altice USA priced 64M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

ENOC

EnerNOC

$5.40

-0.05 (-0.92%)

09:50
06/22/17
06/22
09:50
06/22/17
09:50
Hot Stocks
Breaking Hot Stocks news story on EnerNOC 

EnerNOC trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAFE

Safety, Income and Growth

09:49
06/22/17
06/22
09:49
06/22/17
09:49
Syndicate
Breaking Syndicate news story on Safety, Income and Growth »

Safety, Income and Growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

09:49
06/22/17
06/22
09:49
06/22/17
09:49
General news
Bloomberg Consumer Comfort Index Level data reported »

Week of 6/18 Bloomberg…

SAFE

Safety, Income and Growth

09:47
06/22/17
06/22
09:47
06/22/17
09:47
Syndicate
Breaking Syndicate news story on Safety, Income and Growth »

Safety, Income and Growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

MSFT

Microsoft

$70.27

0.36 (0.51%)

09:46
06/22/17
06/22
09:46
06/22/17
09:46
Initiation
Microsoft initiated  »

Microsoft initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.